Form 4: Elevation Oncology Director Granted 35,000 Stock Options with Aisling Capital Retaining Pecuniary Interest

Elevation Oncology, Inc. director Steve Elms was granted 35,000 stock options with an exercise price of $0.3051, vesting over one year, though the pecuniary interest belongs to Aisling Capital.

Summary

• Steve Elms, a director and 10% owner of Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options on June 5, 2025.
• The stock options have an exercise price of $0.3051 per share.
• The options are scheduled to vest 100% on the one-year anniversary of the grant date, which is June 5, 2026, contingent upon Mr. Elms' continued provision of service to the Issuer.
• The expiration date for these stock options is June 4, 2035.
• Although granted to Mr. Elms in his capacity as a director, the pecuniary interest in these securities belongs entirely to Aisling Capital, where Mr. Elms is an employee, in accordance with Aisling Capital's policies.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal of alignment and incentive, although the indirect pecuniary interest slightly tempers the direct individual incentive.

Positives

• The grant of 35,000 stock options to a director aims to align management incentives with shareholder value, as the options become valuable if the stock price rises above the exercise price of $0.3051.
• The long expiration date of June 4, 2035, provides a significant window for the options to potentially become in-the-money.

Negatives

• The pecuniary interest in the granted stock options belongs to Aisling Capital, not directly to Mr. Elms, which may slightly dilute the direct personal incentive for the individual director.

Risks

• The value of the stock options is contingent on Elevation Oncology's stock price exceeding the exercise price of $0.3051; if the stock price remains below this level, the options may expire worthless.
• The vesting of the options is subject to the reporting person's continued service to the Issuer, meaning forfeiture if service ceases before the vesting date.

Future Outlook

This Form 4 filing details a specific equity grant to a director and does not contain broader forward-looking statements or guidance regarding the company's future performance or strategic outlook beyond the vesting and expiration terms of the options themselves.

Industry Context

This Form 4 filing reports an individual insider transaction (stock option grant) and does not provide broader industry context or trends. Such grants are common practice in the biotechnology and pharmaceutical sectors to incentivize directors and align their interests with long-term company performance.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information for direct comparison to specific industry benchmarks, comparable companies, or project results. Stock option grants to directors are a common form of compensation across publicly traded companies, particularly in the biotech sector, aiming to align director incentives with shareholder value creation.

Related Party Transactions

• The stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of Elevation Oncology. Pursuant to Aisling Capital's policies, Mr. Elms does not have any right to the securities, and Aisling Capital is entitled to receive all pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholder value creation, as the options gain value if the stock price increases.

Next Steps

• The stock options are scheduled to vest 100% on June 5, 2026, subject to continued service by the reporting person.

Key Dates

Keywords

Elevation Oncology, ELEV, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Aisling Capital